<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00918034</url>
  </required_header>
  <id_info>
    <org_study_id>LSO-OL012</org_study_id>
    <nct_id>NCT00918034</nct_id>
  </id_info>
  <brief_title>Study of Light-Activated Talaporfin Sodium in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)</brief_title>
  <official_title>A Phase 2 Study to Evaluate the Safety and Effectiveness of Using the Litx™ BPH System in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) Who Are Candidates for Interventional Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Light Sciences Oncology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Light Sciences Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2 study to evaluate the safety and effectiveness of light-activated&#xD;
      talaporfin sodium in patients with LUTS due to benign prostatic hyperplasia (BPH).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 2 study to evaluate the safety and effectiveness of using light-activated&#xD;
      talaporfin sodium in patients with LUTS due to BPH who are candidates for interventional&#xD;
      therapy.&#xD;
&#xD;
      The eligible patient will undergo placement of a proprietary drug activator into the&#xD;
      prostatic urethra. Following the placement of the drug activator, patients will receive&#xD;
      talaporfin sodium at 1 mg/kg intravenously by slow push over 3-5 minutes. Fifteen minutes&#xD;
      after injection a light dose of 100 Joules per centimeter (J/cm) will be delivered at 20&#xD;
      mW/cm to each patient for a treatment duration of 1 hour 23 minutes.&#xD;
&#xD;
      SAE reporting will occur from the day of treatment (Day 0) through end of study (month 12),&#xD;
      inclusive. Any SAE that is still ongoing at the end of the study will be followed until&#xD;
      assessed as chronic, stable or resolved.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of light-activated talaporfin sodium by recording of Adverse Events; Preliminary effectiveness of light-activated talaporfin sodium by evaluating the International Prostate Symptom Score (IPSS) along with Bother Score (BS).</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <condition>Lower Urinary Tract Symptoms</condition>
  <arm_group>
    <arm_group_label>LS11 (talaporfin sodium)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>talaporfin sodium</intervention_name>
    <description>LS11 (talaporfin sodium) dose of 1mg/kg will be administered intravenously by slow push (3-5 minutes)</description>
    <arm_group_label>LS11 (talaporfin sodium)</arm_group_label>
    <other_name>LS11</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transurethral illumination with light emitting diodes</intervention_name>
    <description>A light dose of 100 Joules per centimeter (J/cm) will be delivered at 20 mW/cm to each patient for a treatment duration of 1 hour 23 minutes</description>
    <arm_group_label>LS11 (talaporfin sodium)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Placement</intervention_name>
    <description>Placement of device in prostate urethra</description>
    <arm_group_label>LS11 (talaporfin sodium)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males, aged 50 years or older with prior diagnosis of BPH;&#xD;
&#xD;
          2. Patients may be eligible whether or not they are on medication for LUTS due to BPH.&#xD;
&#xD;
          3. Patients who are candidates for interventional therapy;&#xD;
&#xD;
          4. Patients who understand and have the ability to sign written informed consent prior to&#xD;
             any study procedures and/or discontinuation of exclusionary medications;&#xD;
&#xD;
          5. Patients with an International Prostate Symptom Score of ≥ 15 points;&#xD;
&#xD;
          6. Patients with moderate to severe BPH (Bother Score ≥ 3);&#xD;
&#xD;
          7. Maximum urinary flow rate (Qmax) ≤ 15 mL/sec;&#xD;
&#xD;
          8. Post void residual volume (PVR) ≤ 300 mL;&#xD;
&#xD;
          9. Length of prostatic urethra ≥ 4.0 cm.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with any previous minimally invasive or surgical intervention for BPH.&#xD;
&#xD;
          2. Patients who are currently enrolled in or who have enrolled in another clinical trial&#xD;
             for any disease within the past 30 days.&#xD;
&#xD;
          3. Patients with an active urinary tract infection.&#xD;
&#xD;
          4. Patients with a urethral stricture.&#xD;
&#xD;
          5. Patients with interstitial cystitis.&#xD;
&#xD;
          6. Patients with a predominant middle lobe obstruction.&#xD;
&#xD;
          7. Patients who have evidence or history of prostate or bladder cancer or carcinoma in&#xD;
             situ of the bladder.&#xD;
&#xD;
          8. Patients with an abnormal digital rectal exam suggestive of carcinoma of the prostate.&#xD;
&#xD;
          9. Patients with an abnormal digital rectal exam suggestive of an indurated nodule.&#xD;
&#xD;
         10. Patients with a PSA of &gt; 10 ng/ml. If the PSA is 4-10 ng/ml, local standard of care&#xD;
             should be pursued to ensure the possibility of prostate cancer is followed up and&#xD;
             ruled out prior to, entry into the study.&#xD;
&#xD;
         11. Patients who had a biopsy of the prostate within the past 6 weeks.&#xD;
&#xD;
         12. Patients with bleeding diathesis.&#xD;
&#xD;
         13. Patients with clinically significant renal or hepatic impairment.&#xD;
&#xD;
         14. Patients with neurological conditions felt to affect the bladder or a history of a&#xD;
             neurogenic or chronically decompensated bladder.&#xD;
&#xD;
         15. Patients who daily use a pad or device for incontinence.&#xD;
&#xD;
         16. Patients who had an episode of unstable angina pectoris, myocardial infarction,&#xD;
             transient ischemic attack, or cerebrovascular accident (stroke) within the past 6&#xD;
             months, or peripheral arterial disease with intermittent claudication or Leriches&#xD;
             syndrome.&#xD;
&#xD;
         17. Patient has an interest in future fertility.&#xD;
&#xD;
         18. Patients with prolonged QT interval at baseline and/or who are currently taking&#xD;
             medication that prolongs QT interval (&quot;prolonged QT interval&quot; defined as &gt; 450 ms).&#xD;
&#xD;
         19. Inadequate organ function as evidenced by the following: Platelet count &lt;100,000/mm3;&#xD;
             WBC &lt;4,000/mm3; Neutrophils &lt;1,800/mm3; Hemoglobin &lt;10 g/dL; AST and ALT &gt;3 x ULN;&#xD;
             Creatinine &gt;1.5 x ULN&#xD;
&#xD;
         20. Known sensitivity to porphyrin-type drugs or known history of porphyria.&#xD;
&#xD;
         21. Inability to avoid bright indoor lighting and sunlight during the first 72 hours after&#xD;
             LS11 administration.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sy-Shi Wang, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Light Sciences Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital Center of Clinical Research</name>
      <address>
        <city>Herston</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bayside Urology</name>
      <address>
        <city>Mentone</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Wolloongabba</city>
        <zip>QLD 4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canterbury Urology Research Trust Hiatt Chambers St. George's Medical Centre</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roundhay Medical Centre</name>
      <address>
        <city>Nelson</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tauranga Urology Research, Ltd.</name>
      <address>
        <city>Tauranga</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellington Urology Research Group Wakefield Urology</name>
      <address>
        <city>Wellington</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kensington Hospital Cardinal Points Specialist Centre</name>
      <address>
        <city>Whangarei</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>June 9, 2009</study_first_submitted>
  <study_first_submitted_qc>June 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2009</study_first_posted>
  <last_update_submitted>November 14, 2012</last_update_submitted>
  <last_update_submitted_qc>November 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BPH</keyword>
  <keyword>LUTS</keyword>
  <keyword>talaporfin sodium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Talaporfin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

